Table 1.

Human studies on TNF-α inhibitiona

ReferenceStudy TypenDiagnosis (n)InterventionRemission (n)Follow-Up (mo)
(45)Uncontrolled trial6WGCS, CTX, IFX56 to 24
(46)Case study1WGCS, CTX, IFX17
(47)Uncontrolled trial32WG/MPACS, S/T, CTX, AZ, MTX, MMF, IFX28Maximum 12
(54)Uncontrolled trial10WG (7)/other (3)CS, IFXbCR 5; PR 56
(55)Case report1Pauci-immune NCGNCS, S/T, IFX112
(56)Controlled trial181WGCS, CTX or MTX, AZ, S/T, ETA or placeboExperimental 69.7%; control 75.3%>9 (mean 27)
  • a AZ, azathioprine; CR, complete remission; CS, corticosteroids; CTX, cyclophosphamide; ETA, etanercept; IFX, infliximab; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; MTX, methotrexate; PR, partial remission; S/T, sulfamethoxazole/trimethoprim; WG, Wegener’s granulomatosis.

  • b Two patients with severe disease received additional therapy with CTX and with MTX and MMF, respectively.